Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Jiankangyuan Ranks Among China's Top 500 Manufacturing Enterprises in 2022, Innovation Empowers Pharmaceutical Manufacturing Vitality
Published Time：
2022-09-08
On September 6, the China Enterprise Confederation and the China Entrepreneur Association held a press conference in Beijing to release the "2022 Top 500 Chinese Enterprises" list and its analysis report, along with a series of lists such as the "2022 Top 500 Chinese Manufacturing Enterprises." In this selection, Joincare Pharmaceutical Group Industry Co., Ltd. was ranked among the "2022 Top 500 Chinese Manufacturing Enterprises."
This year marks the 18th consecutive year that the China Enterprise Confederation has released this list. Zhu Hongren, Party Secretary, Executive Vice President and Chairman of the China Enterprise Confederation, highlighted the performance of the Top 500 Chinese Manufacturing Enterprises: The entry threshold for the "2022 Top 500 Chinese Manufacturing Enterprises" was 14.778 billion yuan, an increase of 3.688 billion yuan year-on-year; total operating revenue reached 47.11 trillion yuan, a year-on-year increase of 17.09%; and net profit reached 1.47 trillion yuan, a year-on-year increase of 24.47%. All three indicators reached record highs.
Leading manufacturing enterprises have become the main force of innovation. The "2022 Top 500 Chinese Manufacturing Enterprises" continued to increase R&D investment, reaching 1.06 trillion yuan, a year-on-year increase of 18.76%; R&D intensity was 2.37%, a slight increase of 0.07 percentage points year-on-year. HealthGen, with operating revenue of 15.904 billion yuan in 2021, a year-on-year increase of approximately 17.62%; net profit attributable to shareholders of listed companies of 1.328 billion yuan, a year-on-year increase of approximately 18.57%; and total R&D investment of 1.85 billion yuan, a year-on-year increase of 47.75%, was ranked on the list.
For many years, HealthGen Pharmaceutical Group has continuously focused on China's large health industry, paying attention to investment in innovative technologies and the construction of R&D platforms. Based on a mature R&D platform for innovative drugs and high-barrier complex preparations, it has made extensive pipeline layouts in areas with significant clinical needs, such as respiratory, digestive, assisted reproduction, mental health, and oncology. It has developed and launched many blockbuster innovative drugs and high-barrier complex preparation products, strongly building the group's diversified product matrix and drug pipeline under research. In recent years, it has gradually broken through the "bottleneck" development in the sub-sector with multiple high-quality inhalation products, becoming the first enterprise in the respiratory drug field to break the international market monopoly, successfully achieving coverage of all categories of asthma and COPD inhalation treatment drugs in existing and research varieties, and quickly opening up and covering the domestic market through national negotiations and centralized procurement.
At the same time, HealthGen continues to explore externally, making full use of external scientific research and commercialization resources, such as strategic cooperation with scientific research institutions and innovative companies such as the Chinese Academy of Sciences and Tencent Quantum Laboratory, and investment in cutting-edge biotechnology companies. Based on the technology platform formed over many years of cultivation, HealthGen uses clinical value as its guide, laying out R&D projects with high short-term certainty and cutting-edge technologies with long-term growth potential, such as AI innovative drug molecular design, PROTAC (Proteolysis-Targeting Chimeras), synthetic biology, gene editing, and cell therapy, to expand its own product matrix and R&D pipeline and achieve sustainable development.
In addition, HealthGen adheres to the development concept of green, healthy, and sustainable development, improving environmental protection, quality standards, and requirements, setting environmental goals, strengthening the monitoring of energy consumption, pollutant emissions, and other environmental protection information in production and operation, implementing energy conservation and emission reduction, and green production, and actively responding to China's macro vision of "achieving carbon neutrality by 2060." In the 2021 annual sponge city construction fund reward review work organized by the Shenzhen Sponge City Construction Office, HealthGen's wholly-owned subsidiary, Shenzhen Haibin Pharmaceutical Co., Ltd., won the Excellent Construction Award for Sponge City Construction Projects and the Social Capital New Construction Projects (including demolition and reconstruction) Supporting Sponge Facilities Award for its green and healthy project "Haibin Pharmaceutical Factory Area."
In the past two months, many biopharmaceutical companies have been investigated by institutions, and institutional investigations have paid more attention to the transformation and opportunities for turning around difficulties brought about by technological innovation. As one of the representatives of Shenzhen enterprises, HealthGen stated that it will continue to increase investment in R&D, rapidly promote product transformation and landing, and improve the company's R&D and production system, truly putting the concept of high-quality development into practice and consolidating its position and layout in advantageous and emerging fields.
The following attachment is an excerpt from the "2022 Top 500 Chinese Manufacturing Enterprises" list.
Disclaimer: The market is risky, and choices should be made cautiously! This article is for reference only and does not constitute a basis for trading.
Source: Phoenix Finance
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.